Table 2. Summary of Agents in Clinical Trials.

compound identifier	molecular target	clinical phase	NCT reference	indications
SM04690, 1	CLK2/DYRK1A	phase 2	NCT03727022	knee osteoarthritis
		phase 2	NCT03706521	knee osteoarthritis
SM04755, 2	CLK2/DYRK1A	phase 2	NCT03229291	tendinopathy
		phase 1	NCT02191761	colorectal, gastric, hepatic and pancreatic cancer
		phase 1	NCT03502434	tendinopathy
SM08502, 3	pan-CLKs/DYRK1A	phase 1	NCT03355066	advanced solid tumors
SM04554, 4	not reported	phase 2/3	NCT03742518	androgenetic alopecia
		phase 2	NCT02503137	androgenetic alopecia
		phase 2	NCT02275351	androgenetic alopecia
PRI-724, 6	CBP	phase 2	NCT03620474	hepatitis b and c, liver cirrhosis
			NCT04047160	primary biliary cholangitis, liver cirrhosis
C-82, 7	CBP	phase 2	NCT02349009	systemic scleroderma
			NCT02432027	psoriasis
CWP-291, 8	Sam68	phase 1/2	NCT03055286	acute myeloid leukemia
		phase 1	NCT02426723	multiple myeloma
		phase 1	NCT01398462	acute myeloid leukemia, myelofibrosis
LGK974, 10	Porcupine	phase 1	NCT02278133	metastatic colorectal cancer
		phase 1	NCT01351103	multiple solid malignancies
		phase 2	NCT02649530	squamous cell carcinoma (withdrawn)
OMP-54F28, 18	Wnts	phase 1	NCT02069145	liver cancer
		phase 1	NCT02092363	ovarian cancer
		phase 1	NCT02050178	pancreatic cancer
		phase 1	NCT01608867	solid tumors
OMP-18R5, 19	FZD 1,2,5,7,8	phase 1	NCT01345201	solid tumors
		phase 1	NCT02005315	pancreatic cancer
		phase 1	NCT01957007	solid tumors
		phase 1	NCT01973309	metastatic breast cancer
BI-905677, 20	LRP5/LRP6	phase 1	NCT03604445	solid tumors
DKN-01, 24	DKK1	phase 2	NCT03645980	liver cancer
		phase 2	NCT04166721	metastatic esophageal and gastric cancer
		phase 2	NCT03837353	prostate cancer
		phase 2	NCT03395080	gynecological cancers
Foxy-5, 25	Wnt5a	phase 1	NCT02655952	metastatic breast, colon and prostate cancer
		phase 2	NCT03883802	colon cancer